- Market Capitalization, $K 115,741,256
- Shares Outstanding, K 2,504,138
- Annual Sales, $ 42,135 M
- Annual Income, $ 5,101 M
- 60-Month Beta 0.60
- Price/Sales 2.87
- Price/Cash Flow 8.94
- Price/Book 1.77
|Period||Period Low||Period High||Performance|
| || |
-0.18 (-0.39%)since 10/18/19
| || |
+3.39 (+7.96%)since 08/20/19
| || |
+1.32 (+2.96%)since 11/20/18
Protalix (PLX) successfully completes the pre-BLA meeting and gets FDA acceptance for using accelerated approval pathway for the BLA submission of Fabry disease candidate, pegunigalsidase alfa.
USA News Group - A stunning revelation came back in April, when an Oxford published study pointed to only 3% of the cancer drugs tested between 2000 and 2015 were approved to treat patients, whereas another...
The Zacks Analyst Blog Highlights: Chevron, HSBC, Sanofi, Sony and Moody's
Top Stock Reports for Chevron, HSBC & Sanofi
Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.
GlaxoSmithKline's (GSK) late-stage study evaluating Nucala succeeds in reducing flares in patients with Hypereosinophilic Syndrome.
Inovio's (INO) loss in the third quarter meets estimates while revenues miss the same. Lead vaccine candidate VGX-3100 is in focus.
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.
Emergent (EBS) rides high on both earnings and revenues beat in the third quarter. ACAM2000 and Narcan drive revenues.
|Nasdaq Composite ETF|
|Intl Momentum Factor Ishares Edge MSCI ETF|
|Total Intl Stock Ishares Core MSCI ETF|
|Pacer Trendpilot European Index ETF|
|ACWI Ishares MSCI ETF|